LAUSR

Key Points Question What is the mode of death and the association of dapagliflozin with cause-specific death in patients with heart failure with improved ejection fraction (HFimpEF)? Findings In this post hoc analysis of the DELIVER trial including 6263 participants, 1151 participants had HFimpEF. The distribution of mode of death was similar in those with HFimpEF compared with those with LVEF consistently greater than 40%, and dapagliflozin was associated with less cardiovascular death relative to placebo in HFimpEF, primarily due to lower rates of sudden death. Meaning The findings indicate that sodium-glucose transport protein 2 inhibitor therapy may help reduce cardiovascular mortality in patients with HFimpEF.